###begin article-title 0
Lack of association of genetic variants in genes of the endocannabinoid system with anorexia nervosa
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 406 410 406 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CNR1</italic>
###xml 412 416 412 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FAAH</italic>
###xml 418 423 418 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAAA </italic>
###xml 427 432 427 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MGLL </italic>
Several lines of evidence indicate that the central cannabinoid receptor 1 (CNR1) as well as the major endocannabinoid degrading enzymes fatty acid amide hydrolase (FAAH), N-acylethanolamine-hydrolyzing acid amidase (NAAA) and monoglyceride lipase (MGLL) are implicated in mediating the orexigenic effects of cannabinoids. The aim of this study was to analyse whether nucleotide sequence variations in the CNR1, FAAH, NAAA and MGLL genes are associated with anorexia nervosa (AN).
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 231 235 231 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CNR1</italic>
###xml 237 241 237 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FAAH</italic>
###xml 243 248 243 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAAA </italic>
###xml 251 256 251 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MGLL </italic>
###xml 285 292 <span type="species:ncbi:9606">patient</span>
###xml 466 474 <span type="species:ncbi:9606">patients</span>
We analysed the association of a previously described (AAT)n repeat in the 3' flanking region of CNR1 as well as a total of 15 single nucleotide polymorphisms (SNPs) representative of regions with restricted haplotype diversity in CNR1, FAAH, NAAA or MGLL in up to 91 German AN trios (patient with AN and both biological parents) using the transmission-disequilibrium-test (TDT). One SNP was additionally analysed in an independent case-control study comprising 113 patients with AN and 178 normal weight controls. Genotyping was performed using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, ARMS-PCR or using 3730xl capillary sequencers.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 203 208 203 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CNR1 </italic>
###xml 361 369 <span type="species:ncbi:9606">patients</span>
The TDT revealed no evidence for association for any of the SNPs or the (AAT)n repeat with AN (all two-sided uncorrected p-values > 0.05). The lowest p-value of 0.11 was detected for the A-allele of the CNR1 SNP rs1049353 for which the transmission rate was 59% (95% confidence interval 47%...70%). Further genotyping of rs1049353 in 113 additional independent patients with AN and 178 normal weight controls could not substantiate the initial trend for association (p = 1.00).
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 67 71 67 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CNR1</italic>
###xml 73 93 73 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FAAH, NAAA and MGLL </italic>
As we found no evidence for an association of genetic variation in CNR1, FAAH, NAAA and MGLL with AN, we conclude that genetic variations in these genes do not play a major role in the etiology of AN in our study groups.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 145 146 145 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 147 148 147 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 293 294 293 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 506 507 506 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 640 641 640 641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 642 643 642 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 644 645 644 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 646 647 646 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 367 375 <span type="species:ncbi:9606">patients</span>
Anorexia nervosa (AN) is an eating disorder with unknown etiology. The multifactorial pathogenesis of AN has been emphasized in various studies [1-3]. Accordingly, heritability estimates derived from twin studies revealed that 58-76% of the variance of AN can be explained by genetic factors [4]. The highest incidence for the development of AN is around puberty and patients with AN are typically characterized by an abnormal eating behaviour with disturbances of attitudes towards body weight and shape [5]. Therefore, it is reasonable that genetic factors regulating food intake and body weight are implicated in the pathogenesis of AN [1,2,6,7].
###end p 11
###begin p 12
###xml 192 193 188 189 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 375 376 371 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 498 501 494 495 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
###xml 542 543 536 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 544 546 538 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 560 562 554 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 563 565 557 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 699 705 693 699 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ob/ob </italic>
###xml 709 715 703 709 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db </italic>
###xml 731 737 725 731 <italic xmlns:xlink="http://www.w3.org/1999/xlink">fa/fa </italic>
###xml 840 846 834 840 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ob/ob </italic>
###xml 911 913 905 907 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1181 1182 1175 1176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 1392 1393 1386 1387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 1394 1395 1388 1389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 552 558 <span type="species:ncbi:9606">humans</span>
###xml 715 719 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 737 741 <span type="species:ncbi:10116">rats</span>
###xml 846 850 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 1021 1029 <span type="species:ncbi:9606">patients</span>
###xml 1128 1136 <span type="species:ncbi:9606">patients</span>
One of the endogenous systems that, due to its therapeutic potential in the treatment of obesity, recently reached scientific interest is the endocannabinoid system. Both exogenous (e.g. Delta9-tetrahydrocannabinol) and endogenous cannabinoids (e.g. anandamide and 2-arachidonoylglycerol (2-AG)) stimulate food intake through activation of the cannabinoid receptor 1 (CNR1) [8]. In contrast, inhibition of CNR1 signalling through administration of the selective inverse agonist rimonabant (Acomplia(R)) decreases food intake in both rodents [9-11] and humans [12,13]. The endocannabinoid system further interacts with the leptinergic system; obese rodents with disturbed leptin signal transduction (ob/ob and db/db mice as well as fa/fa rats) show elevated levels of anandamide and 2-AG in the hypothalamus. Vice versa, leptin treatment of ob/ob mice decreased hypothalamic levels of both, anandamide and 2-AG [11]. Accordingly, compared to age matched normal weight controls, serum levels of anandamide are increased in patients with AN. Additionally, plasma levels of leptin are negatively correlated with anandamide in both, patients with AN and normal weight healthy controls [2]. In light of these observations, it has previously been suggested that the endocannabinoid system might be implicated in the etiology of AN, in particular through its interaction with the leptinergic system [2,7].
###end p 12
###begin p 13
###xml 184 185 184 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 186 188 186 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 417 418 417 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 419 421 419 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 551 552 551 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 553 555 553 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 556 558 556 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 766 767 766 767 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 768 769 768 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 20 28 <span type="species:ncbi:405018">cardinal</span>
###xml 160 168 <span type="species:ncbi:9606">patients</span>
###xml 533 541 <span type="species:ncbi:9606">patients</span>
Hypoleptinemia is a cardinal feature of prolonged semi-starvation that entails various metabolic and neuroendocrine alterations which are typically observed in patients with acute AN [5,14] The most prominent neuroendocrine alterations mediated by semi-starvation induced hypoleptinemia include amenorrhea, osteopenia/osteoporosis, and alterations of the hypothalamic-pituitary-gonadal (HPG) and -adrenal (HPA) axis [5,14]. Additionally, several lines of evidence indicate that hypoleptinemia entails development of hyperactivity in patients with AN [5,14-18]. However, the implication of the endocannabinoid system in body weight regulation together with its interaction with the leptinergic system makes it a plausible system implicated in the pathogenesis of AN [2,7].
###end p 13
###begin p 14
###xml 81 83 81 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 120 122 120 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 243 244 243 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 245 247 245 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 248 250 248 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 441 443 441 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 556 558 556 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 559 561 559 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 704 706 704 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 707 709 707 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 807 809 807 809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 810 812 810 812 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 924 926 924 926 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1133 1138 1133 1138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CNR1 </italic>
###xml 1211 1231 1211 1231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FAAH, NAAA and MGLL </italic>
The most prominent endocannabinoids are N-arachidonoylethanolamine (anandamide) [19] and 2-arachidonoylglycerol (2-AG) [20]. Both are synthesised through cells on demand and undergo a rapid degradation through specific hydrolases and lipases [8,21,22]. The most prominent endocannabinoid degrading enzymes are the fatty acid amide hydrolase (FAAH), the N-acylethanolamine-hydrolyzing acid amidase (NAAA) and the monoglyceride lipase (MGLL) [23]. FAAH is a membrane-bound 60-65 kDa protein that is widely distributed throughout the brain and the periphery [23,24]. Under alkaline conditions, FAAH rapidly inhibits the orexigenic effects of anandamide by degrading it to ethanolamine and arachidonic acid [25,26]. NAAA is an enzyme with similar function but has, in contrast to FAAH, its pH optimum at 4.5-5 [27,28]. The monoglyceride lipase (MGLL) is a serine hydrolase that hydrolyses 2-AG in glycerol and arachidonic acid [22]. As endocannabinoids stimulate food intake through activation of CNR1 and as FAAH, NAAA and MGLL counteract the orexigenic effects of endocannabinoids through their rapid degradation, genetic variation of CNR1 leading to decreased receptor signalling as well as genetic variation of FAAH, NAAA and MGLL leading to increased enzyme activity might be implicated in the etiology of AN.
###end p 14
###begin p 15
###xml 73 77 73 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CNR1</italic>
###xml 79 83 79 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FAAH</italic>
###xml 85 90 85 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAAA </italic>
###xml 94 99 94 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MGLL </italic>
###xml 184 186 184 186 <sub xmlns:xlink="http://www.w3.org/1999/xlink">n </sub>
###xml 222 227 222 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CNR1 </italic>
###xml 322 327 322 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CNR1 </italic>
###xml 386 391 386 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FAAH </italic>
###xml 447 452 447 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAAA </italic>
###xml 504 509 504 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MGLL </italic>
###xml 767 770 767 770 <sub xmlns:xlink="http://www.w3.org/1999/xlink">14 </sub>
###xml 787 792 787 792 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CNR1 </italic>
###xml 889 892 889 892 <sub xmlns:xlink="http://www.w3.org/1999/xlink">13 </sub>
###xml 991 993 991 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1040 1045 1040 1045 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FAAH </italic>
###xml 1222 1224 1222 1224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 1242 1244 1242 1244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 1251 1256 1251 1256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CNR1 </italic>
###xml 1472 1474 1472 1474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 549 556 <span type="species:ncbi:9606">patient</span>
###xml 949 957 <span type="species:ncbi:9606">patients</span>
We performed association studies to analyse whether allelic variation in CNR1, FAAH, NAAA and MGLL is related to the AN phenotype. We therefore genotyped the previously described (AAT)n repeat in the 3' flanking region of CNR1 as well as a total of 15 SNPs representative of regions with restricted haplotype diversity in CNR1 (rs2180619, rs806379, rs1535255, rs2023239 and rs1049353), FAAH (rs932816, rs324420, rs324419, rs2295632 and rs873978), NAAA (rs2292534, rs6532046, rs10518142 and rs874546) and MGLL (rs893294) in up to 91 German AN trios (patient with AN and both biological parents). Genotyping was performed using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry or allele specific polymerase chain reaction (ARMS-PCR). The AAT14 repeat allele of CNR1 has recently been found to be associated with the binge eating/purging type of AN whereby the AAT13 repeat allele tended to be preferentially transmitted to patients with the restricting type of AN [29]. Furthermore, SNP rs324420 (c.385C/A) in the FAAH gene, leading to decreased enzyme activity and thus increased levels of endocannabinoids and presumably increased food intake, was recently found to be associated with obesity [30] and drug abuse [31]. The CNR1 haplotype comprising the minor alleles of SNP rs806379 (T-allele), rs1535255 (G-allele) and rs2023239 (C-allele) has further been shown to be associated with drug and alcohol abuse in European and African Americans [32].
###end p 15
###begin title 16
Methods
###end title 16
###begin p 17
###xml 63 65 63 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 110 122 <span type="species:ncbi:9606">participants</span>
The ascertainment strategy was previously described in detail [33]. Written informed consent was given by all participants and in the case of minors, by their parents. The study was approved by the ethics committees of the Universities of Marburg and Duisburg-Essen and carried out according to the Declaration of Helsinki.
###end p 17
###begin p 18
###xml 0 25 0 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Study group 1 (AN trios) </italic>
###xml 124 125 120 121 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 209 210 201 202 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 47 55 <span type="species:ncbi:9606">patients</span>
Study group 1 (AN trios) comprised 91 (3 male) patients with AN (mean age 15.72 +/- 2.04 years, mean BMI 15.42 +/- 2.39 kg/m2) and both biological parents (mean age 46.73 +/- 5.67, mean BMI 26.22 +/- 4.16 kg/m2).
###end p 18
###begin p 19
###xml 0 35 0 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Study group 2 (cases and controls) </italic>
###xml 376 377 372 373 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 483 484 475 476 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 597 598 585 586 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 743 744 727 728 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 889 891 873 875 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 48 56 <span type="species:ncbi:9606">patients</span>
###xml 70 78 <span type="species:ncbi:9606">patients</span>
###xml 149 157 <span type="species:ncbi:9606">patients</span>
###xml 290 298 <span type="species:ncbi:9606">patients</span>
###xml 514 522 <span type="species:ncbi:9606">patients</span>
###xml 750 758 <span type="species:ncbi:9606">patients</span>
Study group 2 (cases and controls) included 204 patients with AN (113 patients with AN independent from study group 1). The 113 (7 male) independent patients included 65 (3 male) individuals with acute AN and 48 (4 male) individuals from a catamnestic study with a history of AN. The acute patients had a mean age of 22.47 +/- 11.67 years and a mean BMI of 14.81 +/- 2.29 kg/m2. The catamnestic individuals had a mean age of 33.60 +/- 7.22 years and a mean BMI of 20.78 +/- 2.05 kg/m2. In total, the 204 (10 male) patients had a mean age of 22.13 +/- 10.03 years, a mean BMI of 16.46 +/- 3.30 kg/m2. The control group comprised 178 healthy normal weight individuals with a mean age of 24.58 +/- 2.56 years and a mean BMI of 21.76 +/- 1.08 kg/m2. All patients with AN fulfilled the diagnostic criteria for AN according to the diagnostic and statistical manual of mental disorders (DSM-IV) [34].
###end p 19
###begin p 20
###xml 158 163 158 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CNR1 </italic>
###xml 231 233 231 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 240 245 240 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CNR1 </italic>
###xml 424 429 424 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CNR1 </italic>
###xml 481 482 481 482 <underline xmlns:xlink="http://www.w3.org/1999/xlink">7</underline>
###xml 495 498 495 498 <sub xmlns:xlink="http://www.w3.org/1999/xlink">out</sub>
###xml 538 541 538 541 <sub xmlns:xlink="http://www.w3.org/1999/xlink">out</sub>
###xml 585 587 585 587 <sub xmlns:xlink="http://www.w3.org/1999/xlink">in</sub>
###xml 628 630 628 630 <sub xmlns:xlink="http://www.w3.org/1999/xlink">in</sub>
Genotyping was performed using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS, Sequenom, San Diego, CA). Only the CNR1 SNP rs1049353 was genotyped using ARMS-PCR as described previously [35]. The CNR1 (AAT) trinucleotide repeat was genotyped using 3730xl capillary sequencers (Applied Biosystems) and GeneMapper software (Version 4.0, Applied Biosystems). Primers for analyses of CNR1 variations were derived from genomic entry AL136096.7; rs1049353 Fout: 5'-GGA CTC GGA CTG CCT GCA CAA A-3'; Rout: 5'-AAA TTC TTT TCC TGT GCT GCC AGG G-3', Fin: 5'-CAG AAA GCT GCA TCA AGA GCC CG-3', Rin: 5'-GAC ATG GTT ACC TTG GCA ATC TTG CCT-3' (product size outer primers: 175 bp, G-allele: 120 bp, A-allele: 105 bp); (AAT) trinucleotide repeat: F (FAM-labelled): 5'-CCT TCT CCC AGC ACA ATC AT-3', R: 5'-TAC ATC TCG GTG TGT GAT GTT CC A TGT TCC-3' (PCR-product size based on genomic entry AL136096.7: 277 bp). SNP assays for analyses with MALDI-TOF mass spectrometry were designed with the SpectroDesigner software (Sequenom). For validity of genotypes, alleles were rated independently by at least two experienced individuals. Discrepancies were resolved unambiguously either by reaching consensus or by retyping.
###end p 20
###begin p 21
###xml 98 100 98 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 585 590 585 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CNR1 </italic>
The family-based association analyses were done applying transmission disequilibrium tests (TDT) [36] while the software FAMHAP (v16; ) was used to investigate the haplotypes consisting of the genotyped SNPs within the respective genes. Power considerations for the A-allele of rs1049353 were performed using the program Quanto (v 1.2.3; ) at the one-sided significance level of 0.05. Here, we assumed an AN prevalence of 0.5% and an allele frequency of 0.26 (accoding to , CEU sample). Exact Cochran-Armitage trend test, implemented in SAS, was applied to test for association of the CNR1 SNP rs1049353 in case-control data. If not indicated otherwise, all reported p-values are two-sided and were not corrected for multiple testing as none of the null hypotheses was rejected. A significance level of alpha = 0.05 (two-sided) was applied.
###end p 21
###begin title 22
Results
###end title 22
###begin p 23
###xml 118 120 118 120 <sub xmlns:xlink="http://www.w3.org/1999/xlink">n </sub>
###xml 142 143 142 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 170 175 170 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CNR1 </italic>
###xml 582 590 <span type="species:ncbi:9606">patients</span>
###xml 815 823 <span type="species:ncbi:9606">patients</span>
###xml 851 859 <span type="species:ncbi:9606">patients</span>
The Transmission-Disequilibrium Test (TDT) revealed no indication for an association of the analysed SNPs or the (AAT)n repeat with AN (Table 1). For the A-allele of the CNR1 SNP rs1049353 the lowest p-value was 0.11 for an estimated transmission rate of 59% (95% confidence interval 47%...70%). Applying conditional logistic regression on the trio data, we obtained a multiplicative OR of the A-allele at 1.43 (95% confidence interval 0.91...2.25). Hence, in assuming a true effect of such size the power of our consecutive case-control study comprising 113 additional independent patients with AN and 178 normal weight controls would be about 60%. The initial finding, however, could not be substantiated by the case-control approach (exact p = 1.00). Similarly, a combined case-control analysis including the 91 patients from the family-trios (204 patients with AN and 178 controls) revealed no association of the A-allele of rs1049353 with the AN phenotype (exact p = 0.27; multiplicative OR 1.20; 95% CI 0.88...1.65).
###end p 23
###begin p 24
###xml 54 58 54 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CNR1</italic>
###xml 60 65 60 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAAA </italic>
###xml 69 74 69 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MGLL </italic>
Genotypes and TDT results of the analysed variants in CNR1. NAAA and MGLL in the AN trios
###end p 24
###begin p 25
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1 </sup>
###xml 74 76 72 74 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 161 163 159 161 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3 </sup>
###xml 309 311 307 309 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
###xml 355 357 353 355 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5 </sup>
###xml 403 405 401 403 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 449 451 447 449 <sup xmlns:xlink="http://www.w3.org/1999/xlink">7 </sup>
###xml 491 493 489 491 <sup xmlns:xlink="http://www.w3.org/1999/xlink">8 </sup>
###xml 385 393 <span type="species:ncbi:9606">patients</span>
###xml 431 439 <span type="species:ncbi:9606">patients</span>
1 All SNPs were tested for Hardy-Weinberg equilibrium (exact p >/= 0.05); 2 The TGC haplotype comprises the minor alleles of rs806379, rs1535255, and rs2023239; 3 Numbers are given according to genomic entry AL136096.7 and the translation start codon (nt+1 is the A of ATG); SNP alleles correspond to dbSNP ; 4 Number of anorexia nervosa trios genotyped; 5 Genotype frequencies in the patients with AN; 6 Allele frequencies in the patients with AN; 7 Transmission rate of the minor alleles; 8 for TDT
###end p 25
###begin p 26
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CNR1 </italic>
###xml 186 188 186 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 299 304 299 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CNR1 </italic>
###xml 369 371 369 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 372 374 372 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 375 377 375 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 396 399 396 399 <sub xmlns:xlink="http://www.w3.org/1999/xlink">13 </sub>
###xml 406 409 406 409 <sub xmlns:xlink="http://www.w3.org/1999/xlink">14 </sub>
###xml 546 548 546 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 889 894 889 894 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CNR1 </italic>
###xml 911 916 911 916 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FAAH </italic>
###xml 936 941 936 941 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAAA </italic>
The CNR1 haplotype comprising the minor alleles of rs806379, rs1535255 and rs2023239 (TGC), previously found to be associated with polysubstance abuse in European and African Americans [32], revealed likewise no evidence for an association with AN in our study groups. The allele frequencies of the CNR1 AAT trinucleotide repeat were in accordance to previous results [29,37,38]. However, the AAT13 and AAT14 repeat alleles, previously found to be preferentially transmitted to the restricting and binge eating/purging type of AN, respectively, [29] did not indicate evidence for an association with AN in our samples (the global test for transmission disequilibrium indicated p = 0.35). Further haplotype analyses resulted in lack of transmission disequilibrium for all haplotypes, including those solely comprising frequently transmitted alleles (p of global test for haplotypes of five CNR1 SNPs: 0.66; five FAAH SNPs: 0.45 and four NAAA SNPs: 0.72).
###end p 26
###begin title 27
Discussion
###end title 27
###begin p 28
###xml 93 97 93 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CNR1</italic>
###xml 99 118 99 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FAAH, NAAA or MGLL </italic>
###xml 252 257 252 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CNR1 </italic>
###xml 279 287 <span type="species:ncbi:9606">patients</span>
###xml 380 388 <span type="species:ncbi:9606">patients</span>
###xml 459 467 <span type="species:ncbi:9606">patients</span>
###xml 488 496 <span type="species:ncbi:9606">patients</span>
###xml 600 608 <span type="species:ncbi:9606">patients</span>
We observed no evidence for a transmission disequilibrium for any of the 15 analysed SNPs in CNR1, FAAH, NAAA or MGLL as assessed by the TDT. The strongest effect with an estimated transmission rate of 59% hinting at a preferential transmission of the CNR1 rs1049353 A-allele to patients with AN was not substantiated in a subsequent case-control study comprising 113 independent patients with AN and 178 healthy controls. Also, combining the 113 independent patients with AN with the 91 patients from study group 1 did not alter this lack of evidence for an association of the rs1049353 A-allele to patients with AN. Contrary to our initial expectation of an effect size of 1.43 estimated from the trio sample, the true effect of this allele may be more moderate to be detected by our, even pooled, relatively small case-control sample.
###end p 28
###begin p 29
###xml 16 21 16 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CNR1 </italic>
###xml 235 237 235 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 303 305 303 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 306 308 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 309 311 309 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 318 323 318 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CNR1 </italic>
###xml 431 433 431 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 527 530 527 530 <sub xmlns:xlink="http://www.w3.org/1999/xlink">14 </sub>
###xml 537 540 537 540 <sub xmlns:xlink="http://www.w3.org/1999/xlink">13 </sub>
###xml 558 562 558 562 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CNR1</italic>
###xml 60 68 <span type="species:ncbi:9606">patients</span>
###xml 635 643 <span type="species:ncbi:9606">patients</span>
###xml 766 774 <span type="species:ncbi:9606">patients</span>
Even though the CNR1 SNP rs1049353 has not been analysed in patients with AN before, the G-allele of rs1049353 was recently found to be associated with obesity in a small case-control study comprising obese and normal weight Italians [39]. However, several other studies could not confirm this finding [35,40,41]. The CNR1 TGC haplotype previously found to be associated with polysubstance abuse in European and African Americans [32] revealed likewise no evidence for a transmission disequilibrium in our samples. Also the AAT14 and AAT13 repeat alleles of CNR1, which has previously been reported to be preferentially transmitted in patients with the binge eating/purging or restricting type of AN, respectively, were not found to be preferentially transmitted to patients with AN in our study. However, it has to be considered that the moderate to low sample size used in this study might have contributed to the observed lack of association. Additionally, it can not be ruled out that other variants, that are not in linkage disequilibrium with the here analysed variants, might contribute to the pathogenesis of AN.
###end p 29
###begin p 30
###xml 102 104 102 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 118 120 118 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 121 123 121 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 151 152 147 148 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 271 273 267 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 274 276 270 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 418 419 410 411 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 472 473 460 461 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 554 556 542 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 813 815 801 803 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 816 818 804 806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 110 116 <span type="species:ncbi:9606">humans</span>
###xml 231 239 <span type="species:ncbi:9606">patients</span>
###xml 343 351 <span type="species:ncbi:9606">patients</span>
Exogenous and endogenous cannabinoids stimulate food intake and promote weight gain in both, rodents [42] and humans [12,13]. Oral application of Delta9-THC further increases food intake and entails weight restoration in cachectic patients receiving cancer chemotherapy [43,44]. Only one small trial comprising 11 (of which three dropped out) patients with AN has focused on body weight gain after treatment with Delta9-THC and found no effect of oral application of Delta9-THC in doses up to 30 mg/day on body weight gain after four weeks of treatment [45]. However, in light of the small sample size, this observation has to be regarded with caution, especially as THC induced weight gain was compared to diazepam, for which animal studies also indicate a stimulation of body weight gain after its application [46,47].
###end p 30
###begin p 31
###xml 170 172 170 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 196 200 196 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ObRb</italic>
###xml 203 205 203 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 217 219 217 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 220 222 220 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 264 268 264 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BDNF</italic>
###xml 271 273 271 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 274 276 274 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 314 323 314 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF-&#945;</italic>
###xml 326 328 322 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 479 484 475 480 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BDNF </italic>
###xml 517 519 513 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 600 602 596 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 869 871 865 867 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 934 936 930 932 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 590 598 <span type="species:ncbi:9606">patients</span>
###xml 661 669 <span type="species:ncbi:9606">patients</span>
Various association studies for AN have, with only limited success, focused on genes implicated in the regulation of food intake, as e.g. on the genes coding for leptin [48], the leptin receptor (ObRb) [49], ghrelin [50,51], the brain derived neurotrophic factor (BDNF) [52-55] or the tumor necrosis factor-alpha (TNF-alpha) [56]. Most of the respective studies yielded negative results. However, Ribases et al. (2003) reported strong association of the Val66Met polymorphism of BDNF with the restricting type of AN [52]. Additionally, this variant was associated with minimum BMI in these patients [52]. Replication analyses of this variant in 1,142 Caucasian patients with eating disorders from five European countries confirmed the association of this variant with all eating disorder subtypes including AN, AN-restricting type, AN-binge-eating/purging type and BN [53]. However, not all studies were able to confirm this finding [55].
###end p 31
###begin title 32
Conclusion
###end title 32
###begin p 33
###xml 68 70 68 70 <sub xmlns:xlink="http://www.w3.org/1999/xlink">n </sub>
###xml 97 101 97 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CNR1</italic>
###xml 103 123 103 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FAAH, NAAA and MGLL </italic>
###xml 201 218 201 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CNR1, FAAH, NAAA </italic>
###xml 222 227 222 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MGLL </italic>
In summary, we did not find evidence for an association of the (AAT)n repeat and several SNPs in CNR1, FAAH, NAAA and MGLL with AN in our samples. We thus conclude that the here analysed variations in CNR1, FAAH, NAAA and MGLL at least do not seem to play a major role in the genetic etiology of AN in our study groups.
###end p 33
###begin title 34
Competing interests
###end title 34
###begin p 35
The authors declare that they have no competing interests.
###end p 35
###begin title 36
Authors' contributions
###end title 36
###begin p 37
###xml 424 431 <span type="species:ncbi:9606">patient</span>
TDM carried out the allele specific PCR, participated in design and interpretation of data and drafted the manuscript. KR and JK carried out the capillary sequencing. KR further participated in design and interpretation of data and revised the manuscript critically. GB participated in the design and interpretation of data. TTN and AS performed the statistical analysis under supervision of HS. WH and BH-D participated in patient recruitment and interpretation of data. PL and TM carried out the molecular genetic studies using MALDI-TOF mass spectrometry. JH and AH conceived the design and participated in coordination and interpretation of data; helped to draft the manuscript and revised it critically.
###end p 37
###begin title 38
Acknowledgements
###end title 38
###begin p 39
###xml 118 122 118 122 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Plus</sup>
This work was supported by grants from the Federal Ministry of Education and Research (NGFN2: 01GS0482, 01GS0483; NGFNPlus: 01GS0820), the European Union (FP6 LSHMCT-2003-503041) and the Deutsche Forschungsgemeinschaft (DFG; HE 1446/4-1). The skillful technical assistance of Jitka Andrae is highly appreciated.
###end p 39
###begin article-title 40
Genetic risk factors in eating disorders
###end article-title 40
###begin article-title 41
Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa
###end article-title 41
###begin article-title 42
Genetic epidemiology, endophenotypes, and eating disorder classification
###end article-title 42
###begin article-title 43
Genetic and environmental influences on anorexia nervosa syndromes in a population-based twin sample
###end article-title 43
###begin article-title 44
The role of leptin in anorexia nervosa: clinical implications
###end article-title 44
###begin article-title 45
Eating disorders in females: genetics, pathophysiology, and treatment
###end article-title 45
###begin article-title 46
Leptin, ghrelin, and endocannabinoids: Potential therapeutic targets in anorexia nervosa
###end article-title 46
###begin article-title 47
The endocannabinoid system and its therapeutic exploitation
###end article-title 47
###begin article-title 48
Appetite suppression and weight loss after the cannabinoid antagonist SR 141716
###end article-title 48
###begin article-title 49
###xml 134 138 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice
###end article-title 49
###begin article-title 50
Leptin-regulated endocannabinoids are involved in maintaining food intake
###end article-title 50
###begin article-title 51
###xml 123 131 <span type="species:ncbi:9606">patients</span>
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study
###end article-title 51
###begin article-title 52
###xml 62 70 <span type="species:ncbi:9606">patients</span>
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
###end article-title 52
###begin article-title 53
###xml 17 25 <span type="species:ncbi:9606">patients</span>
###xml 67 71 <span type="species:ncbi:10116">rats</span>
Hyperactivity in patients with anorexia nervosa and in semistarved rats: evidence for a pivotal role of hypoleptinemia
###end article-title 53
###begin article-title 54
###xml 59 63 <span type="species:ncbi:10116">rats</span>
Leptin suppresses semi-starvation induced hyperactivity in rats: implications for anorexia nervosa
###end article-title 54
###begin article-title 55
###xml 61 69 <span type="species:ncbi:9606">patients</span>
Elevated physical activity and low leptin levels co-occur in patients with anorexia nervosa
###end article-title 55
###begin article-title 56
The contribution of anxiety and food restriction on physical activity levels in acute anorexia nervosa
###end article-title 56
###begin article-title 57
###xml 67 75 <span type="species:ncbi:9606">patients</span>
Physical activity and restlessness correlate with leptin levels in patients with adolescent anorexia nervosa
###end article-title 57
###begin article-title 58
Isolation and structure of a brain constituent that binds to the cannabinoid receptor
###end article-title 58
###begin article-title 59
2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain
###end article-title 59
###begin article-title 60
Biosynthesis and inactivation of endocannabinoids: relevance to their proposed role as neuromodulators
###end article-title 60
###begin article-title 61
A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation
###end article-title 61
###begin article-title 62
Molecular biology of the enzymes that degrade endocannabinoids
###end article-title 62
###begin article-title 63
###xml 106 109 <span type="species:ncbi:10116">rat</span>
Characterization of the kinetics and distribution of N-arachidonylethanolamine (anandamide) hydrolysis by rat brain
###end article-title 63
###begin article-title 64
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
###end article-title 64
###begin article-title 65
###xml 80 84 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase
###end article-title 65
###begin article-title 66
Molecular characterization of N-acylethanolamine-hydrolyzing acid amidase, a novel member of the choloylglycine hydrolase family with structural and functional similarity to acid ceramidase
###end article-title 66
###begin article-title 67
The N-acylethanolamine-hydrolyzing acid amidase (NAAA)
###end article-title 67
###begin article-title 68
Association study of cannabinoid receptor gene (CNR1) alleles and anorexia nervosa: differences between restricting and binging/purging subtypes
###end article-title 68
###begin article-title 69
Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH)
###end article-title 69
###begin article-title 70
###xml 23 28 <span type="species:ncbi:9606">human</span>
A missense mutation in human fatty acid amide hydrolase associated with problem drug use
###end article-title 70
###begin article-title 71
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human cannabinoid receptor 1: 5' exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse
###end article-title 71
###begin article-title 72
###xml 51 59 <span type="species:ncbi:9606">children</span>
Beta 3-adrenergic-receptor allele distributions in children, adolescents and young adults with obesity, underweight or anorexia nervosa
###end article-title 72
###begin article-title 73
###xml 104 112 <span type="species:ncbi:9606">children</span>
No evidence for an involvement of variants in the cannabinoid receptor gene (CNR1) in obesity in German children and adolescents
###end article-title 73
###begin article-title 74
Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM)
###end article-title 74
###begin article-title 75
Cannabinoid receptor gene (CNR1): association with i.v. drug use
###end article-title 75
###begin article-title 76
Association study of cannabinoid receptor gene (CNR1) alleles and drug dependence
###end article-title 76
###begin article-title 77
Association between cannabinoid type-1 receptor polymorphism and body mass index in a southern Italian population
###end article-title 77
###begin article-title 78
###xml 107 110 <span type="species:ncbi:9606">men</span>
The G1422A variant of the cannabinoid receptor gene (CNR1) is associated with abdominal adiposity in obese men
###end article-title 78
###begin article-title 79
Endocannabinoid receptor 1 gene variations increase risk for obesity and modulate body mass index in European populations
###end article-title 79
###begin article-title 80
The emerging role of the endocannabinoid system in endocrine regulation and energy balance
###end article-title 80
###begin article-title 81
Delta 9-tetrahydrocannabinol in clinical oncology
###end article-title 81
###begin article-title 82
Cancer cachexia and cannabinoids
###end article-title 82
###begin article-title 83
A double-blind trial of delta 9-tetrahydrocannabinol in primary anorexia nervosa
###end article-title 83
###begin article-title 84
###xml 90 94 <span type="species:ncbi:10116">rats</span>
Possible involvement of dopamine D-1 and D-2 receptors in diazepam-induced hyperphagia in rats
###end article-title 84
###begin article-title 85
###xml 77 81 <span type="species:ncbi:10116">rats</span>
Effects of repeated intravenous administration of diazepam on food intake in rats
###end article-title 85
###begin article-title 86
No evidence for involvement of the leptin gene in anorexia nervosa, bulimia nervosa, underweight or early onset extreme obesity: identification of two novel mutations in the coding sequence and a novel polymorphism in the leptin gene linked upstream region
###end article-title 86
###begin article-title 87
Single nucleotide polymorphisms in the leptin receptor gene: studies in anorexia nervosa
###end article-title 87
###begin article-title 88
Association of ghrelin receptor gene polymorphism with bulimia nervosa in a Japanese population
###end article-title 88
###begin article-title 89
No association of the Arg51Gln and Leu72Met polymorphisms of the ghrelin gene with anorexia nervosa or bulimia nervosa
###end article-title 89
###begin article-title 90
Met66 in the brain-derived neurotrophic factor (BDNF) precursor is associated with anorexia nervosa restrictive type
###end article-title 90
###begin article-title 91
Association of BDNF with anorexia, bulimia and age of onset of weight loss in six European populations
###end article-title 91
###begin article-title 92
Association of BDNF with restricting anorexia nervosa and minimum body mass index: a family-based association study of eight European populations
###end article-title 92
###begin article-title 93
###xml 140 148 <span type="species:ncbi:9606">patients</span>
Mutation screen of the brain derived neurotrophic factor gene (BDNF): identification of several genetic variants and association studies in patients with obesity, eating disorders, and attention-deficit/hyperactivity disorder
###end article-title 93
###begin article-title 94
Analysis of tumor necrosis factor-alpha gene promoter polymorphisms in anorexia nervosa
###end article-title 94

